Go Pro
→ I went to a party with Elon... (From Stansberry Research) (Ad)tc pixel
NASDAQ:TAOX

Synaptogenix Q3 2025 Earnings Report

Synaptogenix logo
$4.31 -0.01 (-0.32%)
As of 10:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Synaptogenix EPS Results

Actual EPS
-$1.56
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
$2.41 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synaptogenix Announcement Details

Quarter
Q3 2025
Date
11/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Synaptogenix Earnings Headlines

TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor
July 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-appoints-bittensor-investor-and-author-mark-jeffrey-as-advisor-302820337.html
TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI
June 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-set-to-join-the-russell-microcap-index-as-a-leading-public-gateway-to-decentralized-ai-302801330.html
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.tc pixel
September 24 at 1:00 AM  |  Decentralized Masters (Ad)
TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation
November 18, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-and-yuma-asset-management-to-host-livestream-on-x-bittensor-tao-and-deai-innovation-302618425.html
Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys
November 11, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tradr-set-to-debut-etfs-targeting-bloom-energy-celestica-nano-nuclear-and-synopsys-302611818.html
TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds
November 4, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-announces-initial-750-000-investment-in-yuma-asset-managements-subnet-funds-302603960.html
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:TAOX) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. The company’s research has centered on synaptic function and the potential to improve memory and cognition.

Synaptogenix’s primary development program has involved bryostatin-1, an investigational drug studied for the treatment of Alzheimer’s disease and other conditions involving cognitive impairment. The company has also explored potential applications in related neurological disorders, although its product candidates are investigational and have not been approved for commercial use.

The company was formerly known as Neurotrope, Inc. and adopted the Synaptogenix name as part of a corporate rebranding. Its activities have primarily involved research and clinical development in the United States. Synaptogenix has historically traded under the Nasdaq symbol SNPX; the symbol TAOX may not correspond to the company.

View Synaptogenix Profile
Earnings Tools